Cost-effectiveness analysis of baseline testing for resistance-associated polymorphisms to optimise treatment duration in genotype 1 non-cirrhotic treatment-naive patients with chronic hepatitis C virus

Treatment Naïve ◽

Baseline Testing

Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimise Treatment Duration in Genotype 1 Non-Cirrhotic Treatment-Naïve Patients with Chronic Hepatitis C Virus

Value in Health ◽

10.1016/j.jval.2018.04.043 ◽

2018 ◽

Vol 21 ◽

pp. S9

Author(s):

CG Fawsitt ◽

P Vickerman ◽

G Cooke ◽

NJ Welton

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Cost Effectiveness ◽

Hepatitis C ◽

Treatment Duration ◽

Genotype 1 ◽

Effectiveness Analysis ◽

Treatment Naïve ◽

Baseline Testing

Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus

Value in Health ◽

10.1016/j.jval.2019.08.012 ◽

2020 ◽

Vol 23 (2) ◽

pp. 180-190 ◽

Cited By ~ 1

Author(s):

Christopher G. Fawsitt ◽

Peter Vickerman ◽

Graham S. Cooke ◽

Nicky J. Welton ◽

Eleanor Barnes ◽

...

Keyword(s):

Chronic Hepatitis ◽

Treatment Outcome ◽

Hepatitis C Virus ◽

Cost Effectiveness ◽

Hepatitis C ◽

Genotype 1 ◽

Effectiveness Analysis ◽

Treatment Naïve ◽

Baseline Testing

Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection

Alimentary Pharmacology & Therapeutics ◽

10.1111/apt.12871 ◽

2014 ◽

Vol 40 (6) ◽

pp. 657-675 ◽

Cited By ~ 50

Author(s):

S. Saab ◽

S. C. Gordon ◽

H. Park ◽

M. Sulkowski ◽

A. Ahmed ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Genotype 1 ◽

Virus Genotype ◽

Effectiveness Analysis ◽

Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal

Applied Health Economics and Health Policy ◽

10.1007/s40258-012-0007-8 ◽

2013 ◽

Vol 11 (1) ◽

pp. 65-78 ◽

Cited By ~ 28

Author(s):

Elamin H. Elbasha ◽

Jagpreet Chhatwal ◽

Shannon A. Ferrante ◽

Antoine C. El Khoury ◽

Pedro A. Laires

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Genotype 1 ◽

Virus Genotype ◽

Effectiveness Analysis ◽

Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia

Value in Health Regional Issues ◽

10.1016/j.vhri.2019.09.005 ◽

2020 ◽

Vol 21 ◽

pp. 164-171

Author(s):

Asrul Akmal Shafie ◽

Muhammad Radzi Abu Hassan ◽

Siew Chin Ong ◽

Suchin Virabhak ◽

Yuri Sanchez Gonzalez

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Genotype 1 ◽

Virus Genotype ◽

Effectiveness Analysis ◽

PIN29 Cost Effectiveness Analysis of Addition of Telaprevir or Boceprevir to Standard Therapy Versus Standard Therapy Alone for the Treatment of Previously Untreated Chronic Hepatitis-C Virus Genotype 1 Infection

Value in Health ◽

10.1016/j.jval.2012.03.1305 ◽

2012 ◽

Vol 15 (4) ◽

pp. A242 ◽

Cited By ~ 1

Author(s):

S. Ramachandran ◽

R. Mahabaleshwarkar ◽

Y. Yang

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Standard Therapy ◽

Genotype 1 ◽

Virus Genotype ◽

Effectiveness Analysis ◽

Faculty Opinions recommendation of Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718509362.793497944 ◽

2014 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Genotype 1 ◽

Virus Genotype ◽

Effectiveness Analysis ◽

A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus

Value in Health ◽

10.1016/j.jval.2018.12.011 ◽

2019 ◽

Vol 22 (6) ◽

pp. 693-703 ◽

Cited By ~ 5

Author(s):

Christopher G. Fawsitt ◽

Peter Vickerman ◽

Graham Cooke ◽

Nicky J. Welton ◽

Eleanor Barnes ◽

...

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Antiviral Treatment ◽

Genotype 1 ◽

Direct Acting Antiviral ◽

Effectiveness Analysis ◽

Treatment Naïve ◽

Direct Acting

Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options

Journal of Viral Hepatitis ◽

10.1111/jvh.12278 ◽

2014 ◽

Vol 22 (2) ◽

pp. 175-183 ◽

Cited By ~ 14

Author(s):

P. A. Cortesi ◽

A. Ciaccio ◽

M. Rota ◽

J. K. Lim ◽

S. De Salvia ◽

...

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Treatment Options ◽

Genotype 1 ◽

Effectiveness Analysis ◽

Treatment Naïve

Use of the 6 million viral load cut-off to guide treatment duration with ledipasvir/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection: results from the German Hepatitis C-Registry (DHC-R)

Journal of Hepatology ◽

10.1016/s0168-8278(17)31441-1 ◽

2017 ◽

Vol 66 (1) ◽

pp. S519-S520 ◽

Cited By ~ 1

Author(s):

J. Vermehren ◽

C. Athmann ◽

R. Günther ◽

E. Schott ◽

A. Pathil ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Viral Load ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Treatment Duration ◽

Genotype 1 ◽

Virus Genotype ◽